ARTICLE | Clinical News
SR Pharma replaces SRL172 with SRP299 in asthma
September 18, 2000 7:00 AM UTC
SR Pharma (LSE:SPA) said it has developed a new formulation of SRL172, a suspension of killed Mycobacterium vaccae, that is optimized for the treatment of asthma. SPA plans to start a U.K. Phase II do...